Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albinterferon alfa-2b
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Albinterferon alfa-2b is a long-acting, recombinant fusion protein consisting of interferon alpha-2b genetically fused to human serum albumin. This design extends the half-life of interferon alpha, allowing for less frequent dosing compared to conventional or pegylated forms. The drug exerts antiviral and immunomodulatory effects by binding to type I interferon receptors on cell surfaces, leading to the expression of genes that mediate antiviral, antiproliferative, and immune-modulating responses. Albinterferon alfa-2b was developed as a potential treatment for chronic hepatitis C and was investigated as an alternative to pegylated interferons. Development was discontinued in 2010 following regulatory feedback[1][2][4][5].
- Brand names
- ZalbinAlbuferon
- Other names
- albumin-interferon alphaalbinterferon alpha-2b
02
Targets
IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on albinterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albinterferon alfa-2b.